Romidepsin in Peripheral and Cutaneous T-Cell Lymphoma: Mechanistic Implications from Clinical and Correlative Data

Romidepsin is an epigenetic agent approved for the treatment of patients with cutaneous or peripheral T-cell lymphoma (CTCL and PTCL). Here we report data in all patients treated on the National Cancer Institute 1312 trial, demonstrating long-term disease control and the ability to retreat patients...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Haematol
Main Authors: Bates, Susan E., Eisch, Robin, Ling, Alex, Rosing, Douglas, Turner, Maria, Pittaluga, Stefania, Prince, H. Miles, Kirschbaum, Mark H., Allen, Steven L., Zain, Jasmine, Geskin, Larisa J., Joske, David, Popplewell, Leslie, Cowen, Edward W., Jaffe, Elaine S., Nichols, Jean, Kennedy, Sally, Steinberg, Seth M., Liewehr, David J., Showe, Louise C., Steakley, Caryn, Wright, John, Fojo, Tito, Litman, Thomas, Piekarz, Richard L.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4675455/
https://ncbi.nlm.nih.gov/pubmed/25891346
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.13400
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados